Hansa Biopharma envisions organ transplantations made available to sensitized patients and for swift inhibition of attacks by the immune system to be brought to patients suffering from autoimmune conditions. The company’s lead candidate drug, IdeS, is primarily developed as a single dose treatment to enable kidney transplantation for sensitized patients.
Hansa Biopharma
Hansa Medical is a Swedish clinical stage drug development company focused on novel immunomodulatory enzymes for the treatment of rare and acute conditions characterized by pathogenic antibodies.
